Eiger BioPharmaceuticals Inc

NAS:EIGR (USA)  
$ 0.30 -0.0142 (-4.44%) 10:08 PM EST
At Loss
Market Cap:
$ 13.35M
Enterprise V:
$ 14.87M
Volume:
100.79K
Avg Vol (2M):
259.63K
Also Trade In:
Volume:
100.79K
At Loss
Avg Vol (2M):
259.63K

Business Description

Eiger BioPharmaceuticals Inc
NAICS : 325414 SIC : 2836
ISIN : US28249U1051
Description
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Name Current Vs Industry Vs History
Cash-To-Debt 0.96
Equity-to-Asset -0.03
Debt-to-Equity -25.52
Debt-to-EBITDA -0.51
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -16.15
Distress
Grey
Safe
Beneish M-Score -3.85
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 28.13
9-Day RSI 40.22
14-Day RSI 44.3
6-1 Month Momentum % -61.94
12-1 Month Momentum % -67.69

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.31
Quick Ratio 3.24
Cash Ratio 2.39
Days Inventory 3598.52
Days Sales Outstanding 65.37
Days Payable 11204.41

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -21.6
Shareholder Yield % -33.53
Name Current Vs Industry Vs History
Gross Margin % 98.17
Operating Margin % -570.32
Net Margin % -590.8
FCF Margin % -566.44
ROE % -237.33
ROA % -88.21
ROIC % -1009.97
ROC (Joel Greenblatt) % -7117.89
ROCE % -106.35

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 0.91
EV-to-EBIT -0.18
EV-to-EBITDA -0.18
EV-to-Revenue 1.01
EV-to-FCF -0.18
Earnings Yield (Greenblatt) % -555.56
FCF Yield % -622.23

Financials (Next Earnings Date:2024-03-15 Est.)

EIGR's 30-Y Financials
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:EIGR

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Eiger BioPharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 14.666
EPS (TTM) ($) -1.97
Beta 2.27
Volatility % 143.01
14-Day RSI 44.3
14-Day ATR ($) 0.052241
20-Day SMA ($) 0.33554
12-1 Month Momentum % -67.69
52-Week Range ($) 0.21 - 2.98
Shares Outstanding (Mil) 44.38

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Eiger BioPharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Eiger BioPharmaceuticals Inc Stock Events

Event Date Price($)
No Event Data

Eiger BioPharmaceuticals Inc Frequently Asked Questions

What is Eiger BioPharmaceuticals Inc(EIGR)'s stock price today?
The current price of EIGR is $0.30. The 52 week high of EIGR is $2.98 and 52 week low is $0.21.
When is next earnings date of Eiger BioPharmaceuticals Inc(EIGR)?
The next earnings date of Eiger BioPharmaceuticals Inc(EIGR) is 2024-03-15 Est..
Does Eiger BioPharmaceuticals Inc(EIGR) pay dividends? If so, how much?
Eiger BioPharmaceuticals Inc(EIGR) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1